Department of Psychiatry, University of Oxford, UK.
Institute of Neuroscience / Institute for Ageing, Newcastle University, Newcastle, UK.
J Alzheimers Dis. 2018;65(4):1377-1383. doi: 10.3233/JAD-180622.
Gait disturbances are some of the earliest changes in dementia and their monitoring presents an opportunity for early diagnosis. The exact relationship between gait and well-established biomarkers of Alzheimer's disease (AD) remains to be clarified. In this study we compared gait-related measures with cerebrospinal fluid (CSF) markers of AD pathology. We recruited seventeen participants with mild AD in a multi-site study and performed gait assessment as well as lumbar punctures to obtain CSF. CSF Aβ42/Aβ40 and Aβ42/Aβ38 correlated positively with measures of variability (step time and step length) in the clinic-based assessments. This was driven by a negative relationship between gait variability and Aβ40 and Aβ38 but not Aβ42.The amyloid ratios and gait variability measures were also associated with more severe functional impairment. We interpret these data as an indication that increasing amyloid production (i.e., increasing Aβ40 and Aβ38) is associated with diminishing cognitive-motor control of gait. These preliminary results suggest that the two amyloid ratios may be a marker of the earliest disturbances in the interplay between cognitive and motor control which characterize dementia.
步态障碍是痴呆症最早出现的变化之一,对其进行监测为早期诊断提供了机会。步态与阿尔茨海默病(AD)已确立的生物标志物之间的确切关系仍有待阐明。在这项研究中,我们比较了与 AD 病理相关的步态测量值与脑脊液(CSF)标志物。我们在一个多地点研究中招募了 17 名轻度 AD 患者,并进行了步态评估以及腰椎穿刺以获得 CSF。CSF Aβ42/Aβ40 和 Aβ42/Aβ38 与基于临床的评估中的变异性(步时和步长)呈正相关。这是由于步态变异性与 Aβ40 和 Aβ38 呈负相关,但与 Aβ42 无关。淀粉样蛋白比值和步态变异性测量值也与更严重的功能障碍相关。我们将这些数据解释为表明,淀粉样蛋白产生增加(即 Aβ40 和 Aβ38 增加)与认知运动控制步态的能力下降有关。这些初步结果表明,这两个淀粉样蛋白比值可能是认知和运动控制相互作用最早出现障碍的标志物,这些障碍是痴呆症的特征。